Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Reuben Gobezie

Orthopaedic Surgery Cleveland, OH Medical Doctor

NPI 1295786770 CMS profile 770996

300 Allen Bradley Dr, Cleveland, OH 44124

Open in the dashboard

General payments

$12,026,947

414 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$539,953 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Reuben Gobezie of Cleveland, OH is reported in the CMS Open Payments database as having received $12,026,947 across 414 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $539,953 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,658,969 21
2024 General $2,341,674 74
2023 General $1,939,191 23
2022 General $1,562,556 65
2021 General $1,460,459 84
2020 General $1,036,523 45
2019 General $1,027,576 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Reuben Gobezie
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Reuben Gobezie were reported at $2,658,969. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Reuben Gobezie Orthopaedic Surgery median Middle half National median
2019 $1,027,576 $644 $140–$2,844 $163
2020 $1,036,523 $312 $75–$1,860 $114
2021 $1,460,459 $520 $117–$2,495 $132
2022 $1,562,556 $598 $128–$2,731 $149
2023 $1,939,191 $461 $128–$2,264 $160
2024 $2,341,674 $497 $134–$2,475 $164
2025 $2,658,969 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $12,026,392 364 payments
  2. Zyla Life Sciences $434 43 payments
  3. Pfizer Inc. $41 2 payments
  4. Smith+Nephew, Inc. $18 1 payment
  5. Medline Industries, Inc. $17 1 payment
  6. Ethicon US, LLC $16 1 payment
  7. Fidia Pharma USA Inc. $15 1 payment
  8. Medtronic, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $11,614,173 29 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $216,845 24 payments
  3. Consulting Fee $180,904 49 payments
  4. Travel and Lodging $9,382 49 payments
  5. Food and Beverage $5,644 263 payments
Products named General payments · program years 2019–2025
  1. Arthrex Arthroplasty & Shoulder Fracture - Implants - Revers Total Shoulder - Modular Glenoid System - MGS Glenospheres $5,312,740 8 payments
  2. ARTHREX Arthroplasty - Implants - Revers Total Shoulder - Modular Glenoid System $4,765,367 12 payments
  3. ARTHREX Arthroplasty - Implants - Revers Total Shoulder - Modular Glenoid System $4,765,367 12 payments
  4. ARTHREX Arthroplasty - Implants - Revers Total Shoulder - Revers $4,765,367 12 payments
  5. Arthrex Arthroplasty & Shoulder Fracture - Implants - Revers Total Shoulder - Modular Glenoid System - MGS Baseplates $2,656,370 4 payments
  6. Arthrex Upper Extremity - Implants - Cerclage - Orthopedic - Knotted $2,656,370 4 payments
  7. Arthrex Arthroplasty & Shoulder Fracture - Implants - Revers Total Shoulder - Revers - Cups $2,656,370 4 payments
  8. Arthrex Arthroplasty & Shoulder Fracture - Implants - Revers Total Shoulder - Modular Glenoid System $2,250,018 4 payments
  9. Arthrex Arthroplasty & Shoulder Fracture - Implants - Revers Total Shoulder - Revers $2,250,018 4 payments
  10. Arthrex Upper Extremity - Implants - Cerclage - Orthopedic $2,250,018 4 payments
  11. Other $23,602,837 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

25

Median for Orthopedic Surgery: 203

Drug cost

$148

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisone Generic 25 $148

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$295,669

Of which drugs: $2,722

Medicare patients

661

Average age 75

Services billed

6,483

370 women, 291 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 25%
Depression 24%
Diabetes 22%
Chronic kidney disease 21%
Osteoporosis 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 327 3,733 $2,722

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

414 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record